Corvus Pharmaceuticals (CRVS) investor relations material

Key clinical results and efficacy

• In Phase I, soquelitinib achieved 75% EASI 75, 25% EASI 90, and 33% IGA 0/1 after 8 weeks, with a mean EASI reduction of 72%, outperforming placebo.

• Efficacy was consistent in patients with prior systemic therapy, including those resistant to dupilumab and JAK inhibitors.

• Responses were durable, with disease control maintained post-treatment and no rapid rebound.

• Placebo-adjusted efficacy was robust, with clear separation of response curves and minimal placebo effect.

• Longer treatment duration led to greater efficacy compared to earlier cohorts.

Safety and tolerability

• No severe or serious adverse events were reported; most AEs were mild to moderate and did not require dose modification.

• No clinically significant lab abnormalities or cases of conjunctivitis were observed.

• Adverse event rates were similar between soquelitinib and placebo groups.

Mechanism of action and biomarker findings

• Soquelitinib is a first-in-class, highly selective ITK inhibitor, sparing RLK and minimizing off-target effects.

• The drug induces T regulatory cells (Tregs), supporting durable remission and immune system rebalancing.

• Biomarker analysis showed reductions in Th2 cells, IL-4, IL-5, IL-17, and TARC, with dose-dependent effects.

• The mechanism is distinct from other agents, affecting multiple cytokines and cell types involved in inflammation.